Gumbleton Matthew相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

BRAF(V600E)-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.

BRAF(V600E)驱动的肺肿瘤发生需要配体介导的ERBB受体信号激活

doi:10.1101/2025.05.04.652129

Dacheux Melanie Angelina, Wu Meng-Jung, Scherzer Michael T, Nillson Monique, Murphy Brandon, Schuman Sophia, Ju Zhenlin, Bivona Trever, Lito Piro, Gumbleton Matthew, Puri Sonam, Akerley Wallace, Wang Jing, Wang Kaiwen, Heymach John, Kinsey Conan G, Negrao Marcelo, McMahon Martin, Vaishnavi Aria

发表日期：2025

文献求助收藏

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult

成人感染新冠病毒后，接受伊匹木单抗/纳武单抗治疗并出现免疫相关不良事件——纹状苔藓

期刊:JAAD Case Reports

doi:10.1016/j.jdcr.2024.05.038

Kenyon, Courtney M; Kelly, Brenna G; Bowen, Anneli R; Gumbleton, Matthew; Deacon, Dekker C

免疫/内分泌

发表日期：2024

文献求助收藏

TTF-1 and immune checkpoint therapy in non-small cell lung cancer

TTF-1 和免疫检查点疗法在非小细胞肺癌中的应用

期刊:Translational Lung Cancer Research

影响因子:3.5

doi:10.21037/tlcr-23-101

Gumbleton, Matthew; Snyder, Eric L

细胞生物学

免疫/内分泌

发表日期：2023

文献求助收藏

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

一项 I 期开放标签研究，旨在评估阿帕替尼（rivoceranib）在二线或后续治疗中对晚期恶性肿瘤患者提高帕博利珠单抗敏感性的安全性和有效性（APPEASE）。

期刊:BMC Research Notes

影响因子:1.7

doi:10.1186/s13104-023-06283-5

Gumbleton, Matthew; Allan, Stephanie; Conway, Hannah; Boucher, Kenneth; Marvin, James; Hawks, Josiah; Burnett, William; Van Brocklin, Matthew; Whisenant, Jonathan; Gilcrease, Glynn; Gupta, Sumati

发表日期：2023

文献求助收藏

SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice

SHIP1 内在调控 NK 细胞信号传导和分化，从而使小鼠对 MHC I 类不匹配的骨髓移植产生耐受性。

期刊:Journal of Immunology

影响因子:3.4

doi:10.4049/jimmunol.1402930

Gumbleton, Matthew; Vivier, Eric; Kerr, William G

细胞生物学

发表日期：2015

文献求助收藏